YungShin Global Holding Corp
TWSE:3705
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.55
62.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
YungShin Global Holding Corp
Interest Income Expense
YungShin Global Holding Corp
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Interest Income Expense
NT$284.3m
|
CAGR 3-Years
265%
|
CAGR 5-Years
44%
|
CAGR 10-Years
20%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Interest Income Expense
-NT$826.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-60%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Interest Income Expense
NT$53.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Interest Income Expense
-NT$181k
|
CAGR 3-Years
84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Interest Income Expense
NT$506.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Interest Income Expense
NT$130.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
26%
|
|
YungShin Global Holding Corp
Glance View
YungShin Global Holding Corp. engages in resources integration and business development. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-01-03. The firm mainly invests in the manufacturing and trading of various medicines, animal medicines, Chinese medicines, health foods, chemicals, cosmetics, soaps, medicated soaps, various detergents, spices, feeds, diagnostic equipment and reagents. The firm also invests in the sales of pharmaceuticals, pharmaceutical raw materials and health food raw materials, as well as the production and sales of chemical drugs and feed additives and other animal products. The main products are antibiotic injection items, various aqueous solutions for medicine and oral tablets of antibiotics, veterinary drug products, medicated feed additives and non-medicated feed additives and others.
See Also
What is YungShin Global Holding Corp's Interest Income Expense?
Interest Income Expense
284.3m
TWD
Based on the financial report for Jun 30, 2024, YungShin Global Holding Corp's Interest Income Expense amounts to 284.3m TWD.
What is YungShin Global Holding Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
20%
Over the last year, the Interest Income Expense growth was 66%. The average annual Interest Income Expense growth rates for YungShin Global Holding Corp have been 265% over the past three years , 44% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
